ID: ALA305908

Max Phase: Preclinical

Molecular Formula: C10H11BrN4O3S2

Molecular Weight: 379.26

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@]1(CSc2nc[nH]n2)S[C@@H]2[C@H](Br)C(=O)N2[C@H]1C(=O)O

Standard InChI:  InChI=1S/C10H11BrN4O3S2/c1-10(2-19-9-12-3-13-14-9)5(8(17)18)15-6(16)4(11)7(15)20-10/h3-5,7H,2H2,1H3,(H,17,18)(H,12,13,14)/t4-,5+,7-,10+/m1/s1

Standard InChI Key:  DVGGIJLCNIHENJ-ASTPYSOASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 379.26

Molecular Weight (Monoisotopic): 377.9456

AlogP: 0.79

#Rotatable Bonds: 4

Polar Surface Area: 99.18

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.63

CX Basic pKa: 0.74

CX LogP: 1.07

CX LogD: -2.32

Aromatic Rings: 1

Heavy Atoms: 20

QED Weighted: 0.45

Np Likeness Score: -0.31

References

1. von Daehne W, Hoffmeyer L, Keiding J.  (1993)  Rearrangement of unsymmetrical azetidinone disulfides to 2-(heterocyclylthiomethyl)penams, a synthetic approach to new -lactamase inhibitors,  3  (11): [10.1016/S0960-894X(01)80933-1]

Source

Source(1):

• Scientific Literature